{"protocolSection": {"identificationModule": {"nctId": "NCT00915772", "orgStudyIdInfo": {"id": "1218.52"}, "secondaryIdInfos": [{"id": "2008-008494-59", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid", "officialTitle": "Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2011-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-06-02", "studyFirstSubmitQcDate": "2009-06-05", "studyFirstPostDateStruct": {"date": "2009-06-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-06-13", "resultsFirstSubmitQcDate": "2012-06-13", "resultsFirstPostDateStruct": {"date": "2012-07-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-04-29", "lastUpdatePostDateStruct": {"date": "2014-05-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "A phase III randomised, double-blind parallel group extension study to investigate the efficacy and safety of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 567, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Linagliptin + metformin bid", "type": "EXPERIMENTAL", "description": "Linagliptin low dose + metformin 500 mg, bid", "interventionNames": ["Drug: Linagliptin + metformin"]}, {"label": "Linagliptin+ metformin bid", "type": "EXPERIMENTAL", "description": "Linagliptin low dose + metformin 1000 mg bid", "interventionNames": ["Drug: Linagliptin+metformin"]}, {"label": "Metformin bid", "type": "ACTIVE_COMPARATOR", "description": "Metformin 1000 mg bid", "interventionNames": ["Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Linagliptin + metformin", "description": "Linagliptin tablet low dose + metformin tablet 500 mg bid", "armGroupLabels": ["Linagliptin + metformin bid"]}, {"type": "DRUG", "name": "Linagliptin+metformin", "description": "Linagliptin low dose tablet + metformin 1000 mg tablet bid", "armGroupLabels": ["Linagliptin+ metformin bid"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin 1000 mg tablet bid", "armGroupLabels": ["Metformin bid"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Frequency of Patients With Adverse Events (AEs)", "description": "This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.", "timeFrame": "54 weeks"}, {"measure": "Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)", "description": "Baseline is defined as Visit 1 of 1218.52.", "timeFrame": "54 weeks"}, {"measure": "Change From Baseline at Week 54 in Pulse Rate", "description": "Baseline is defined as Visit 1 of 1218.52.", "timeFrame": "54 weeks"}, {"measure": "Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology", "timeFrame": "54 weeks"}, {"measure": "Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry", "description": "ULN means upper limit of normal", "timeFrame": "54 weeks"}, {"measure": "Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE", "description": "Frequency of patients with adverse events by treatment, primary system organ class and preferred term", "timeFrame": "Baseline and drug stop (up to 54 weeks) + 7 days"}], "secondaryOutcomes": [{"measure": "Change in HbA1c From Baseline Over Time", "description": "HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.", "timeFrame": "54 weeks"}, {"measure": "Number of Patients With HbA1c <7.0% After 54 Weeks", "timeFrame": "54 weeks"}, {"measure": "Number of Patients With HbA1c <6.5% Over Time", "timeFrame": "54 weeks"}, {"measure": "Number of Patients With HbA1c of at Least <0.5% Over Time", "timeFrame": "54 weeks"}, {"measure": "Change in FPG From Baseline Over Time", "description": "Baseline is defined as visit 1 of 1218.52.", "timeFrame": "54 weeks"}, {"measure": "Number of Patients With Rescue Therapy", "timeFrame": "54 weeks"}, {"measure": "Change in HbA1c From Baseline Over Time", "description": "HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).", "timeFrame": "78 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Signed and dated written informed consent, at the latest by the date of Visit 1\n* Patients completing the entire treatment period of the double-blind study 1218.46, who are not treated with rescue medication (Visit 7)\n\nExclusion criteria:\n\n* Patients who meet one or more of the withdrawal criteria of the treatment period of the previous study 1218.46\n* Pre-menopausal women (last menstruation equal or less than 1 year prior to signing informed consent) who:\n* are nursing or pregnant,\n* or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner and in addition for male partners a barrier method, such as the use of condom with spermicide. No exception will be made.\n* Alcohol abuse within the 3 months prior to informed consent that would interfere with study participation\n* Drug abuse that in the opinion of the investigator would interfere with trial participation\n* Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the study medication", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1218.52.11005 Boehringer Ingelheim Investigational Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "1218.52.11003 Boehringer Ingelheim Investigational Site", "city": "Edmonton", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "1218.52.11002 Boehringer Ingelheim Investigational Site", "city": "Red Deer", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 52.26682, "lon": -113.802}}, {"facility": "1218.52.11006 Boehringer Ingelheim Investigational Site", "city": "Vancouver", "state": "British Columbia", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "1218.52.11008 Boehringer Ingelheim Investigational Site", "city": "Winnipeg", "state": "Manitoba", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "1218.52.11004 Boehringer Ingelheim Investigational Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "1218.52.11007 Boehringer Ingelheim Investigational Site", "city": "Oakville", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.45011, "lon": -79.68292}}, {"facility": "1218.52.11010 Boehringer Ingelheim Investigational Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "1218.52.38502 Boehringer Ingelheim Investigational Site", "city": "Karlovac", "country": "Croatia", "geoPoint": {"lat": 45.48941, "lon": 15.54887}}, {"facility": "1218.52.38503 Boehringer Ingelheim Investigational Site", "city": "Krapinske Toplice", "country": "Croatia", "geoPoint": {"lat": 46.09333, "lon": 15.84333}}, {"facility": "1218.52.38504 Boehringer Ingelheim Investigational Site", "city": "Osijek", "country": "Croatia", "geoPoint": {"lat": 45.55111, "lon": 18.69389}}, {"facility": "1218.52.38505 Boehringer Ingelheim Investigational Site", "city": "Rijeka", "country": "Croatia", "geoPoint": {"lat": 45.32674, "lon": 14.44239}}, {"facility": "1218.52.38501 Boehringer Ingelheim Investigational Site", "city": "Sisak", "country": "Croatia", "geoPoint": {"lat": 45.46611, "lon": 16.37833}}, {"facility": "1218.52.37202 Boehringer Ingelheim Investigational Site", "city": "P\u00e4rnu", "country": "Estonia", "geoPoint": {"lat": 58.38588, "lon": 24.49711}}, {"facility": "1218.52.37201 Boehringer Ingelheim Investigational Site", "city": "Tallin", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "1218.52.37203 Boehringer Ingelheim Investigational Site", "city": "Tallin", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "1218.52.3303D Boehringer Ingelheim Investigational Site", "city": "Aire sur l'Aadour", "country": "France"}, {"facility": "1218.52.3308B Boehringer Ingelheim Investigational Site", "city": "Bischheim", "country": "France", "geoPoint": {"lat": 48.61612, "lon": 7.75343}}, {"facility": "1218.52.3305A Boehringer Ingelheim Investigational Site", "city": "Bourges", "country": "France", "geoPoint": {"lat": 47.08333, "lon": 2.4}}, {"facility": "1218.52.3304F Boehringer Ingelheim Investigational Site", "city": "Bousse", "country": "France", "geoPoint": {"lat": 49.27925, "lon": 6.19525}}, {"facility": "1218.52.3308C Boehringer Ingelheim Investigational Site", "city": "Gambsheim", "country": "France", "geoPoint": {"lat": 48.69209, "lon": 7.88286}}, {"facility": "1218.52.3301A Boehringer Ingelheim Investigational Site", "city": "Grenoble c\u00e9dex", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "1218.52.3305B Boehringer Ingelheim Investigational Site", "city": "Guerigny", "country": "France", "geoPoint": {"lat": 47.08703, "lon": 3.20182}}, {"facility": "1218.52.3304A Boehringer Ingelheim Investigational Site", "city": "Jarny", "country": "France", "geoPoint": {"lat": 49.15736, "lon": 5.87877}}, {"facility": "1218.52.3302D Boehringer Ingelheim Investigational Site", "city": "La Riche", "country": "France", "geoPoint": {"lat": 47.38996, "lon": 0.67072}}, {"facility": "1218.52.9999 Boehringer Ingelheim Investigational Site", "city": "La Riche", "country": "France", "geoPoint": {"lat": 47.38996, "lon": 0.67072}}, {"facility": "1218.52.3307A Boehringer Ingelheim Investigational Site", "city": "La Seyne sur Mer", "country": "France", "geoPoint": {"lat": 43.09818, "lon": 5.88471}}, {"facility": "1218.52.3307E Boehringer Ingelheim Investigational Site", "city": "La Seyne sur Mer", "country": "France", "geoPoint": {"lat": 43.09818, "lon": 5.88471}}, {"facility": "1218.52.3305G Boehringer Ingelheim Investigational Site", "city": "Lury", "country": "France"}, {"facility": "1218.52.3303A Boehringer Ingelheim Investigational Site", "city": "Mont de Marsan", "country": "France", "geoPoint": {"lat": 43.89022, "lon": -0.49713}}, {"facility": "1218.52.3308F Boehringer Ingelheim Investigational Site", "city": "Mundolsheim", "country": "France", "geoPoint": {"lat": 48.64215, "lon": 7.71378}}, {"facility": "1218.52.3305E Boehringer Ingelheim Investigational Site", "city": "Nevers", "country": "France", "geoPoint": {"lat": 46.98956, "lon": 3.159}}, {"facility": "1218.52.3306A Boehringer Ingelheim Investigational Site", "city": "Ortez", "country": "France"}, {"facility": "1218.52.3306C Boehringer Ingelheim Investigational Site", "city": "Orthez", "country": "France", "geoPoint": {"lat": 43.48839, "lon": -0.77244}}, {"facility": "1218.52.3302E Boehringer Ingelheim Investigational Site", "city": "Savonni\u00e8res", "country": "France", "geoPoint": {"lat": 47.34769, "lon": 0.54961}}, {"facility": "1218.52.3303B Boehringer Ingelheim Investigational Site", "city": "St Martin d'Oney", "country": "France", "geoPoint": {"lat": 43.92757, "lon": -0.64133}}, {"facility": "1218.52.3308A Boehringer Ingelheim Investigational Site", "city": "Strasbourg", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "1218.52.3308D Boehringer Ingelheim Investigational Site", "city": "Strasbourg", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "1218.52.3308E Boehringer Ingelheim Investigational Site", "city": "Strasbourg", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "1218.52.3307D Boehringer Ingelheim Investigational Site", "city": "Toulon", "country": "France", "geoPoint": {"lat": 43.12442, "lon": 5.92836}}, {"facility": "1218.52.3302A Boehringer Ingelheim Investigational Site", "city": "Tours", "country": "France", "geoPoint": {"lat": 47.38333, "lon": 0.68333}}, {"facility": "1218.52.49002 Boehringer Ingelheim Investigational Site", "city": "Bad D\u00fcrrheim-Sunthausen", "country": "Germany"}, {"facility": "1218.52.49006 Boehringer Ingelheim Investigational Site", "city": "K\u00f6ln", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"facility": "1218.52.49003 Boehringer Ingelheim Investigational Site", "city": "M\u00fcnchen", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "1218.52.49007 Boehringer Ingelheim Investigational Site", "city": "Schauenburg", "country": "Germany"}, {"facility": "1218.52.91009 Boehringer Ingelheim Investigational Site", "city": "Aurangabad", "country": "India", "geoPoint": {"lat": 19.87757, "lon": 75.34226}}, {"facility": "1218.52.91001 Boehringer Ingelheim Investigational Site", "city": "Bangalore", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "1218.52.91004 Boehringer Ingelheim Investigational Site", "city": "Bangalore", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "1218.52.91012 Boehringer Ingelheim Investigational Site", "city": "Bangalore", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "1218.52.91011 Boehringer Ingelheim Investigational Site", "city": "Bhopal", "country": "India", "geoPoint": {"lat": 23.25469, "lon": 77.40289}}, {"facility": "1218.52.91003 Boehringer Ingelheim Investigational Site", "city": "Chennai", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "1218.52.91020 Boehringer Ingelheim Investigational Site", "city": "Chennai", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "1218.52.91018 Boehringer Ingelheim Investigational Site", "city": "Hyderadad", "country": "India"}, {"facility": "1218.52.91008 Boehringer Ingelheim Investigational Site", "city": "Jaipur", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "1218.52.91002 Boehringer Ingelheim Investigational Site", "city": "Karnataka", "country": "India"}, {"facility": "1218.52.91007 Boehringer Ingelheim Investigational Site", "city": "Karnataka", "country": "India"}, {"facility": "1218.52.91019 Boehringer Ingelheim Investigational Site", "city": "Madurai", "country": "India", "geoPoint": {"lat": 9.91769, "lon": 78.11898}}, {"facility": "1218.52.91013 Boehringer Ingelheim Investigational Site", "city": "Maharashtra", "country": "India"}, {"facility": "1218.52.91015 Boehringer Ingelheim Investigational Site", "city": "Mumbai", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "1218.52.91014 Boehringer Ingelheim Investigational Site", "city": "Nagpru", "country": "India"}, {"facility": "1218.52.91016 Boehringer Ingelheim Investigational Site", "city": "P.O.Trivandrum", "country": "India"}, {"facility": "1218.52.91010 Boehringer Ingelheim Investigational Site", "city": "Pune", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "1218.52.91006 Boehringer Ingelheim Investigational Site", "city": "West Bengal", "country": "India"}, {"facility": "1218.52.37001 Boehringer Ingelheim Investigational Site", "city": "Kaunas", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "1218.52.37004 Boehringer Ingelheim Investigational Site", "city": "Kaunas", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "1218.52.37003 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "1218.52.52006 Boehringer Ingelheim Investigational Site", "city": "Aguascalientes", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "1218.52.52002 Boehringer Ingelheim Investigational Site", "city": "Cuernavaca", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"facility": "1218.52.52004 Boehringer Ingelheim Investigational Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "1218.52.52007 Boehringer Ingelheim Investigational Site", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "1218.52.52008 Boehringer Ingelheim Investigational Site", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "1218.52.52010 Boehringer Ingelheim Investigational Site", "city": "Tijuana", "country": "Mexico", "geoPoint": {"lat": 32.5027, "lon": -117.00371}}, {"facility": "1218.52.52009 Boehringer Ingelheim Investigational Site", "city": "Veracruz", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "1218.52.31004 Boehringer Ingelheim Investigational Site", "city": "'s Hertogenbosch", "country": "Netherlands", "geoPoint": {"lat": 51.69917, "lon": 5.30417}}, {"facility": "1218.52.31005 Boehringer Ingelheim Investigational Site", "city": "'s Hertogenbosch", "country": "Netherlands", "geoPoint": {"lat": 51.69917, "lon": 5.30417}}, {"facility": "1218.52.31001 Boehringer Ingelheim Investigational Site", "city": "Almere", "country": "Netherlands", "geoPoint": {"lat": 52.37535, "lon": 5.25295}}, {"facility": "1218.52.31002 Boehringer Ingelheim Investigational Site", "city": "Beek en Donk", "country": "Netherlands", "geoPoint": {"lat": 51.54158, "lon": 5.62603}}, {"facility": "1218.52.31010 Boehringer Ingelheim Investigational Site", "city": "Breda", "country": "Netherlands", "geoPoint": {"lat": 51.58656, "lon": 4.77596}}, {"facility": "1218.52.31013 Boehringer Ingelheim Investigational Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "1218.52.31014 Boehringer Ingelheim Investigational Site", "city": "Velp", "country": "Netherlands", "geoPoint": {"lat": 51.995, "lon": 5.97361}}, {"facility": "1218.52.31015 Boehringer Ingelheim Investigational Site", "city": "Zoetermeer", "country": "Netherlands", "geoPoint": {"lat": 52.0575, "lon": 4.49306}}, {"facility": "1218.52.40001 Boehringer Ingelheim Investigational Site", "city": "Alba Iulia", "country": "Romania", "geoPoint": {"lat": 46.06667, "lon": 23.58333}}, {"facility": "1218.52.40005 Boehringer Ingelheim Investigational Site", "city": "Galati", "country": "Romania", "geoPoint": {"lat": 45.45, "lon": 28.05}}, {"facility": "1218.52.40003 Boehringer Ingelheim Investigational Site", "city": "Oradea", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"facility": "1218.52.40002 Boehringer Ingelheim Investigational Site", "city": "Ploiesti", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"facility": "1218.52.40004 Boehringer Ingelheim Investigational Site", "city": "Satu Mare", "country": "Romania", "geoPoint": {"lat": 47.79926, "lon": 22.86255}}, {"facility": "1218.52.70001 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1218.52.70002 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1218.52.70003 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1218.52.70004 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1218.52.70006 Boehringer Ingelheim Investigational Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "1218.52.70005 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "1218.52.70007 Boehringer Ingelheim Investigational Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "1218.52.46002 Boehringer Ingelheim Investigational Site", "city": "Goteborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "1218.52.46003 Boehringer Ingelheim Investigational Site", "city": "Malmo", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "1218.52.46005 Boehringer Ingelheim Investigational Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "1218.52.46001 Boehringer Ingelheim Investigational Site", "city": "Uppsala", "country": "Sweden", "geoPoint": {"lat": 59.85882, "lon": 17.63889}}, {"facility": "1218.52.2162A Boehringer Ingelheim Investigational Site", "city": "Bab Sa\u00e2doun Tunis", "country": "Tunisia"}, {"facility": "1218.52.2162B Boehringer Ingelheim Investigational Site", "city": "Bab S\u00e2adoun Tunis", "country": "Tunisia"}, {"facility": "1218.52.9992 Boehringer Ingelheim Investigational Site", "city": "Bab S\u00e2adoun Tunis", "country": "Tunisia"}, {"facility": "1218.52.2161A Boehringer Ingelheim Investigational Site", "city": "Tunis", "country": "Tunisia", "geoPoint": {"lat": 36.81897, "lon": 10.16579}}, {"facility": "1218.52.2161B Boehringer Ingelheim Investigational Site", "city": "Tunis", "country": "Tunisia", "geoPoint": {"lat": 36.81897, "lon": 10.16579}}, {"facility": "1218.52.2163A Boehringer Ingelheim Investigational Site", "city": "Tunis", "country": "Tunisia", "geoPoint": {"lat": 36.81897, "lon": 10.16579}}, {"facility": "1218.52.2163B Boehringer Ingelheim Investigational Site", "city": "Tunis", "country": "Tunisia", "geoPoint": {"lat": 36.81897, "lon": 10.16579}}, {"facility": "1218.52.9991 Boehringer Ingelheim Investigational Site", "city": "Tunis", "country": "Tunisia", "geoPoint": {"lat": 36.81897, "lon": 10.16579}}, {"facility": "1218.52.9993 Boehringer Ingelheim Investigational Site", "city": "Tunis", "country": "Tunisia", "geoPoint": {"lat": 36.81897, "lon": 10.16579}}, {"facility": "1218.52.38003 Boehringer Ingelheim Investigational Site", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "1218.52.38001 Boehringer Ingelheim Investigational Site", "city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "1218.52.38005 Boehringer Ingelheim Investigational Site", "city": "Lvov", "country": "Ukraine", "geoPoint": {"lat": 47.89219, "lon": 31.09319}}, {"facility": "1218.52.38002 Boehringer Ingelheim Investigational Site", "city": "Odessa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "1218.52.38004 Boehringer Ingelheim Investigational Site", "city": "Odessa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "1218.52.38006 Boehringer Ingelheim Investigational Site", "city": "Vinnitsa", "country": "Ukraine", "geoPoint": {"lat": 49.84639, "lon": 37.71861}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "List of publications", "url": "http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.52_Literature.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "In this study, 567 patients were entered and randomised, but only 566 were treated. Therefore the treated set (TS) comprises 566 patients.", "groups": [{"id": "FG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "FG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "FG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "170"}, {"groupId": "FG001", "numSubjects": "225"}, {"groupId": "FG002", "numSubjects": "171"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "134"}, {"groupId": "FG001", "numSubjects": "179"}, {"groupId": "FG002", "numSubjects": "142"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "46"}, {"groupId": "FG002", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "11"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Refused to continue trial medication", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Any other reason", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "BG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "BG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "225"}, {"groupId": "BG002", "value": "171"}, {"groupId": "BG003", "value": "566"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.6", "spread": "10.7"}, {"groupId": "BG001", "value": "56.0", "spread": "10.7"}, {"groupId": "BG002", "value": "55.7", "spread": "10.8"}, {"groupId": "BG003", "value": "55.8", "spread": "10.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "74"}, {"groupId": "BG003", "value": "256"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "120"}, {"groupId": "BG002", "value": "97"}, {"groupId": "BG003", "value": "310"}]}]}]}, {"title": "Body Mass Index (BMI) continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.33", "spread": "5.22"}, {"groupId": "BG001", "value": "29.06", "spread": "4.95"}, {"groupId": "BG002", "value": "28.64", "spread": "4.79"}, {"groupId": "BG003", "value": "29.01", "spread": "4.98"}]}]}]}, {"title": "Baseline weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "81.09", "spread": "18.92"}, {"groupId": "BG001", "value": "79.17", "spread": "18.75"}, {"groupId": "BG002", "value": "78.62", "spread": "16.86"}, {"groupId": "BG003", "value": "79.58", "spread": "18.25"}]}]}]}, {"title": "Baseline Glycosylated haemoglobin (HbA1c) at baseline", "description": "Based upon non-missing data, n=559 (5:1:1 missing in each of the groups respectively)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.48", "spread": "0.99"}, {"groupId": "BG001", "value": "7.64", "spread": "1.04"}, {"groupId": "BG002", "value": "7.35", "spread": "1.12"}, {"groupId": "BG003", "value": "7.50", "spread": "1.06"}]}]}]}, {"title": "Fasting plasma glucose (FPG) at baseline", "description": "Based upon non-missing data, n=544 (6:10:6 missing in each of the groups respectively)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "156.585", "spread": "39.194"}, {"groupId": "BG001", "value": "167.088", "spread": "44.633"}, {"groupId": "BG002", "value": "153.721", "spread": "37.128"}, {"groupId": "BG003", "value": "159.868", "spread": "41.206"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Frequency of Patients With Adverse Events (AEs)", "description": "This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.", "populationDescription": "Treated Set (TS): all screened patients who were documented to have taken at lease 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participant", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "Patients with any AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "149"}, {"groupId": "OG002", "value": "132"}]}]}, {"title": "Patients with severe AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Patients with withdrawal due to AEs (from AE page)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "9"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)", "description": "Baseline is defined as Visit 1 of 1218.52.", "populationDescription": "TS and observed cases (OC)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "214"}, {"groupId": "OG002", "value": "165"}]}], "classes": [{"title": "DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "8.5"}, {"groupId": "OG001", "value": "-0.1", "spread": "7.4"}, {"groupId": "OG002", "value": "0.3", "spread": "8.8"}]}]}, {"title": "SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "12.2"}, {"groupId": "OG001", "value": "-0.2", "spread": "13.2"}, {"groupId": "OG002", "value": "2.2", "spread": "13.6"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline at Week 54 in Pulse Rate", "description": "Baseline is defined as Visit 1 of 1218.52.", "populationDescription": "TS and observed cases (OC)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute (bpm)", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "214"}, {"groupId": "OG002", "value": "164"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "7.7"}, {"groupId": "OG001", "value": "0.6", "spread": "8.3"}, {"groupId": "OG002", "value": "0.1", "spread": "8.3"}]}]}]}, {"type": "PRIMARY", "title": "Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology", "populationDescription": "TS and observed cases (OC)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "170"}]}], "classes": [{"title": "Haematocrit abnormality: <=32%", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Haemoglobin abnormality:Female \u22649.5;Male \u226411.5g/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Red Blood Cells abnormality: < 3* 10^12/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "White Blood Cells abnormal decrease: < 3 * 10^9/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "White Blood Cells abnormal increase: <20.1*10^9/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Platelets abnormal decrease: <= 75* 10^9/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Platelets abnormal increase: >= 700* 10^9/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry", "description": "ULN means upper limit of normal", "populationDescription": "TS and observed cases (OC). In treatment group L2.5+M500, the number of patients analysed was 224 for lactate dehydrogenase abnormality and total bilirubin abnormality due to anailable data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "Eosinophils abnormality : \u2265 10%", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Sodium abnormal decrease: < 130 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Sodium abnormal increase: > 160 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Potassium abnormal decrease: < 3 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Potassium abnormal increase: > 5.8 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Calcium abnormal decrease: < 1.8 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Calcium abnormal increase: > 3 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Phosphate abnormal decrease: < 0.7 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Phosphate abnormal increase: > 1.7 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Aspartate Transaminase abnormality: \u22653xULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Alanine Transaminase (ALT) abnormality: >= 3 x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Alkaline phosphatase abnormality: >= 2 x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "\u03b3-glutamyl transpeptidase (GGT) increase:\u22653ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Lactate dehydrogenase abnormality: >= 3 x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Creatine kinase abnormality: >= 3 x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Amylase: > 1.5 x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Total cholesterol abnormality: > 300 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Creatinine abnormality: >= 1.5 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Total bilirubin abnormality: >= 2 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Triglyceride abnormality: >300 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": "Uric acid abnormality:Female: >10;Male: >11 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Albumin abnormality: <2.5 g/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Bicarbonate abnormal decrease: <21 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c From Baseline Over Time", "description": "HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.", "populationDescription": "TS (OC) with non-missing data at visit", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "Change in HbA1c to week 6 (n=157, 207 and 166)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.41"}, {"groupId": "OG001", "value": "-0.24", "spread": "0.51"}, {"groupId": "OG002", "value": "-0.26", "spread": "0.59"}]}]}, {"title": "Change in HbA1c to week 18 (n=136, 184 and 147)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.56"}, {"groupId": "OG001", "value": "-0.29", "spread": "0.79"}, {"groupId": "OG002", "value": "-0.34", "spread": "0.93"}]}]}, {"title": "Change in HbA1c to week 30 (n=121, 165 and 134)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.82"}, {"groupId": "OG001", "value": "-0.41", "spread": "0.80"}, {"groupId": "OG002", "value": "-0.36", "spread": "0.87"}]}]}, {"title": "Change in HbA1c to week 42 (n=110, 152 and 127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "spread": "0.78"}, {"groupId": "OG001", "value": "-0.35", "spread": "0.80"}, {"groupId": "OG002", "value": "-0.28", "spread": "1.00"}]}]}, {"title": "Change in HbA1c to week 54 (n=98, 132 and 117)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.28", "spread": "0.86"}, {"groupId": "OG002", "value": "-0.24", "spread": "0.91"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With HbA1c <7.0% After 54 Weeks", "populationDescription": "Treated Set with non completers considered as failures (NCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participant", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "168"}, {"groupId": "OG002", "value": "104"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "67"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With HbA1c <6.5% Over Time", "populationDescription": "Treated Set with non completers considered as failures (NCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participant", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "196"}, {"groupId": "OG002", "value": "130"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "41"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With HbA1c of at Least <0.5% Over Time", "populationDescription": "Treated Set with non completers considered as failures (NCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participant", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "176"}, {"groupId": "OG002", "value": "135"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "36"}]}]}]}, {"type": "SECONDARY", "title": "Change in FPG From Baseline Over Time", "description": "Baseline is defined as visit 1 of 1218.52.", "populationDescription": "TS (OC) with non-missing data at visit", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "Change in FPG to week 2 (n=158, 200 and 158)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.36", "spread": "27.86"}, {"groupId": "OG001", "value": "-12.22", "spread": "28.70"}, {"groupId": "OG002", "value": "-10.57", "spread": "28.15"}]}]}, {"title": "Change in FPG to week 6 (n=152, 189 and 157)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.18", "spread": "32.68"}, {"groupId": "OG001", "value": "-13.28", "spread": "27.36"}, {"groupId": "OG002", "value": "-13.46", "spread": "32.97"}]}]}, {"title": "Change in FPG to week 18 (n=133, 174 and 142)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.14", "spread": "43.18"}, {"groupId": "OG001", "value": "-11.76", "spread": "33.10"}, {"groupId": "OG002", "value": "-12.88", "spread": "33.74"}]}]}, {"title": "Change in FPG to week 30 (n=116, 156 and 130)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.22", "spread": "41.67"}, {"groupId": "OG001", "value": "-13.49", "spread": "33.68"}, {"groupId": "OG002", "value": "-13.90", "spread": "32.07"}]}]}, {"title": "Change in FPG to week 42 (n=103, 149 and 124)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.43", "spread": "30.48"}, {"groupId": "OG001", "value": "-9.46", "spread": "33.61"}, {"groupId": "OG002", "value": "-13.10", "spread": "34.96"}]}]}, {"title": "Change in FPG to week 54 (n=93, 132 and 115)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.02", "spread": "29.25"}, {"groupId": "OG001", "value": "-7.24", "spread": "36.27"}, {"groupId": "OG002", "value": "-9.82", "spread": "31.83"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Rescue Therapy", "populationDescription": "TS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of patients", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "163"}, {"groupId": "OG002", "value": "147"}]}]}, {"title": "Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "24"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c From Baseline Over Time", "description": "HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).", "populationDescription": "Non-switcher set (OC) with non-missing data at visit. Only patients who continued on the same treatment in both studies are included", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "78 weeks", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"title": "Change in HbA1c to week 30 (n=102, 103 and 108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.19", "spread": "0.98"}, {"groupId": "OG001", "value": "-1.34", "spread": "0.91"}, {"groupId": "OG002", "value": "-1.74", "spread": "0.98"}]}]}, {"title": "Change in HbA1c to week 42 (n=90, 92 and 95)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.16", "spread": "0.98"}, {"groupId": "OG001", "value": "-1.31", "spread": "0.99"}, {"groupId": "OG002", "value": "-1.62", "spread": "1.05"}]}]}, {"title": "Change in HbA1c to week 54 (n=81, 81 and 87)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.20", "spread": "1.14"}, {"groupId": "OG001", "value": "-1.41", "spread": "1.03"}, {"groupId": "OG002", "value": "-1.73", "spread": "0.99"}]}]}, {"title": "Change in HbA1c to week 66 (n=74, 73 and 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.26", "spread": "1.02"}, {"groupId": "OG001", "value": "-1.42", "spread": "0.93"}, {"groupId": "OG002", "value": "-1.65", "spread": "1.09"}]}]}, {"title": "Change in HbA1c to week 78 (n=66, 66 and 78)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.25", "spread": "0.91"}, {"groupId": "OG001", "value": "-1.32", "spread": "1.06"}, {"groupId": "OG002", "value": "-1.63", "spread": "1.05"}]}]}]}, {"type": "PRIMARY", "title": "Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE", "description": "Frequency of patients with adverse events by treatment, primary system organ class and preferred term", "populationDescription": "Treated Set (TS)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and drug stop (up to 54 weeks) + 7 days", "groups": [{"id": "OG000", "title": "M1000", "description": "Metformin 1000mg monotherapy twice daily"}, {"id": "OG001", "title": "L2.5+M500", "description": "Linagliptin 2.5mg and metformin 500mg twice daily"}, {"id": "OG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5mg and metformin 1000mg twice daily"}, {"id": "OG003", "title": "Post-treat", "description": "7 days follow-up period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "171"}, {"groupId": "OG003", "value": "566"}]}], "classes": [{"title": "Cardiogenic shock", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Supraventricular tachycardia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "54 weeks", "eventGroups": [{"id": "EG000", "title": "M1000", "description": "Metformin 1000 mg twice daily", "seriousNumAffected": 7, "seriousNumAtRisk": 170, "otherNumAffected": 63, "otherNumAtRisk": 170}, {"id": "EG001", "title": "L2.5+M500", "description": "Linagliptin 2.5 mg + Metformin 500 mg twice daily", "seriousNumAffected": 12, "seriousNumAtRisk": 225, "otherNumAffected": 87, "otherNumAtRisk": 225}, {"id": "EG002", "title": "L2.5+M1000", "description": "Linagliptin 2.5 mg + Metformin 1000 mg twice daily", "seriousNumAffected": 14, "seriousNumAtRisk": 171, "otherNumAffected": 77, "otherNumAtRisk": 171}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Cardiac disorder", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Holoprosencephaly", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Dacryocystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Febrile infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 171}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Renal cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 171}]}, {"term": "Calculus bladder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 171}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 171}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 171}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 171}]}, {"term": "Glomerular filtration rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 171}]}, {"term": "Glycosylated haemoglobin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 171}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 171}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 171}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 171}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 14.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 225}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 171}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069476", "term": "Linagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M445", "name": "Linagliptin", "asFound": "Output", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}